A DNA synthesis company using a next-generation silicon-based technology platform.
On June 10 2015, Twist Bioscience closed a $37,000,000 series C funding round. Investors include: Foresite Capital, ARCH Venture Partners, Paladin Capital Group, Venture Investors, Fidelity Management & Research, IlluminaIllumina, Joby Pritzker, and Yuri Milner.
Twist Bioscience was founded in 2013, and made their own high-throughput semiconductor-based DNA synthesis technology. Their technology allows them to overcome many of the barriers faced by other companies trying to manufacture DNA in high volumes. Problems that are overcome by semi-conductor based DNA synthesis are: producing too many errors in the genetic code during the manufacturing process, inability to produce synthetic DNA in high volumes, and producing affordable high quality DNA strands. Twist claims to have successfully industrialized a cost effective, high fidelity, and high through-put DNA synthesis platform capable of synthesizing DNA in high volumes.
Their semiconductor-based DNA synthesis technology greatly improved DNA synthesis. The miniaturizationBy ofminiaturizing the DNA synthesis process madeonto possiblemicrofabricated throughsilicon semiconductorswells and channels, Twist Bioscience has allowed Twistbeen Bioscienceable to improve the throughput of DNA synthesis by a factor of 1000. Throughput is greatly increased because semiconductor based technology allows the chemical reactions necessary for DNA synthesis to be reducedscaled down by a factor of 1,000,000. Twist Bioscience is able to produce 9,600 genes on a single silicon chip using their technology; compared to 1 gene being produced on the same amount of space using traditional DNA synthesis technologies.
LowerReduce cost of introducing new genes into microorganisms that produce chemicals
ImprovesImprove feasibilitythe throughput and reduce the cost of buildinggenetically betterengineering crops
CreateEnable newmore rapid, cheaper protein engineering for drug discovery experiments at a lower cost
Helps lowerLower cost of identifying disease gene targets
Reduce cost and increasedincrease efficiency of CRISPR technology
Next generation sequencing (NGS) verified gene clones with no type II S sequencerestriction restrictionssequences and custom vector onboarding with verification. There is currently a lower limit of 10+ genes (no upper limit ) to place an order that will be ready within 20 business days.
20 business days.
Using combinatorial libraries for focused mutagenesis offers more flexibility and better representation than degenerate approaches. There are no unwantedSpecific codons may be excluded, codon ratio can be controlled, and all libraries are NGS verified.
DNA is being developed as a storage servicesmedium arefor underdevelopmentdigital data. Twist Bioscience is working with Microsoft and the University of Washington to improve data storage using DNA, and have published research demonstrating high-fidelity storage and random-access retrieval of over 200 MB of data, including an OK-Go music video. StoringAs datathe intechnology matures, DNA offerscould offer a low energyhigh-density, longlow-energy, termlong-term and secure data storage solution. Twist Bioscience hasexplains their work on DNA data storage technology as explained in their white paper.
Oligo pools are made to be diverse collections of oligonucleotides toand can be used for applications such as creation of CRISPR sgRNA libraries and high-throughput reporter essays. Oligo pools are made to be highly uniform and accurate for maximal oligo representation and have an error rate of approximately 1:1000 nucleotides (nt). sgRNA libraries and high-throughput reporter essays. Oligo pools are made to be highly uniform and accurate for maximal oligo representation and have an error rate of approximately 1:1000 nucleotides (nt).
upUp to 200 nt
Site saturation libraries are precise and diverse when compared to traditional directed mutagenesis techniques. Each saturation library is verified using NGS technology. Site saturation libraries are precise and diverse when compared to traditional directed mutagenesis techniques. They come free from unwanted codons and can be made to have specific codon ratios.
On May 27th, 2014 twistTwist Bioscience received $5.1 million dollars in funding from the Defense Advanced Research projects Agency (DARPA). The contract was awarded to Twist Bioscience under DARPA's Living Foundries program.
On Feb 10 2014, 2014 twistTwist Bioscience received $9,100,000 in series A funding from Asset Management Ventures (AMV) .
On May 27, 2014, Twist Bioscience receivedcompleted a $26,000,000 after completing their series B funding round. Investors include: DARPA, ARCH Venture Partners, Paladin Capital Group, Yuri Milner, and some undisclosed investors, and some undisclosed investors.
On June 10, 2015, Twist Bioscience receivedclosed a $37,000,000 after completing their series C funding round. Investors include: Foresite Capital, ARCH Venture Partners, Paladin Capital Group, Venture Investors, Fidelity Management & Research, Illumnia, Joby Pritzker, and Yuri Milner, ARCH Venture Partners, Paladin Capital Group, Venture Investors, Fidelity Management & Research, IllumniaIllumina, Joby Pritzker, and Yuri Milner.
On March 27th, 2017, Twist Bioscience receivedclosed a $61,000,000 after completing their series D funding round. Investors include: Foresite Capital., ARCH Venture Partners, Paladin Capital Group, Fidelity Management & Research, Fidelity Management and Research Company, Illumina, Boris Nikolic, Cormorant Asset Management, WuXi Healthcare Ventures, Fidelity Management, Yuri Milner, MerieuxMérieux DeveloppementDéveloppement, ARCH Overage Fund, Foresite Capital Management, WuXi, Corporate Venture Fund, Nick Pritzker, and Joby Pritzker.
On June 14th, 2017, Twist Bioscience receivedclosed a $27,000,000 after completing their series E funding round. Investors include: Biomatics Capital, Reinet Fund S.C.A, F.I.S, NFT Investment Limited, KangMei Group, Bay City Capital, GF Xinde Life Science Investment Fund, 3W Partners Capital, and Ditch Plains Capital Management LP.
On April 3rd 2018, 2018 Twist Bioscience received $50,000,000 in funding from private investors.
In June, 2016, Twist Bioscience became partners with Desktop Genetics —, a company using AI to create CRISPR screens. The partnership focuses on developing and integrating DNA synthesis tools and to design to design research protocols that enhance gene editing research. Desktop geneticsGenetics works with their customers to predictdesign CRISPR sgRNA CRISPR libraries for a cell line before sending this information to Twist Bioscience for sgRNA library synthesis. This partnership claims to aimaims to reduce cost and improve efficiency of gene editing research.
In June 2017, the BioBricks foundation partnered up with Twist Bioscience on the Free Genes project, an initiative to create aan open-source library of 10,000 genes that form biological parts important for synthetic biology. Twist Bioscience will be providing all the DNA that will be used for the project, and BioBricks will assemble a library of useful genes using its team and drawing on support from the scientific community. EverythingAll genetic constructs created through this partnership iswill basedbe onmade afreely available to the public through the Open Material Transfer Agreement, thatwhich allows anyoneany recipient to have freeuse, accessmodify, tocombine, copy, and redistribute the genes (in compliance with applicable biosafety and intellectual property laws).
In July 2017, Quintara Bioscience and Twist Bioscience became business partners, announcing they will be working together to create qBlock Gene Fragment and qGene DNA cloning services. Twist Bioscience will combine their silicon DNA synthesis technology with Quintara Bioscience's sequencing and cloning technologies to deliver gene fragment and cloning services.
Twist Bioscience and Synbio Technologies became partners on July 11th, 2017. The partnership seeks to combine technologies being used at both companies, by offering DNA strands up to 70 kilobases in length. Twist Bioscience will synthesissynthesize DNA strands up to 3.2 kilobases in length before shipping them off to Synbio Technologies for completion. This partnership gives both companies more international presence,: Twist Bioscience in located in FranceSan Francisco, and Synbio Technologies is in China, andso by working together they areplan to be able to offer improved DNA strand products that enhance scientific research for the diagnosis and treatment of disease.
On April 6th, 2016 Twist Bioscience acquired the Israeli software company Genome Compiler for an undisclosed price. Twist plans to use Genome CompilersCompiler's software developers and technology will allow Twist Bioscience to build an an ecommercee-commerce platform that allows customers to create their own gene designs online before ordering;, and haveto aleverage their strong software development team for future projects.
No more activity to show.